WI Public Hearing Tomorrow: Consumer Access to Complementary and Alternative Health Practitioners Bill – Submit Testimony Now
Results of the study on virgin coconut oil (VCO) as dietary supplement among COVID-19 probable and suspect cases showed that 5 of the 29 patients who were served meals with VCO manifested diminishing signs and symptoms as early as the second day, while only one patient served with the same meals but without VCO showed similar improvement.
This is according to the Department of Science and Technology’s Food and Nutrition Research Institute (DOST-FNRI) in a virtual presser dubbed as “Seeing Beyond COVID-19: The VCO Study – Effects of Virgin Coconut Oil among Suspect and Probable Cases” on December 3, 2020.
The VCO Group of patients who were served meals with VCO showed no COVID-19 related symptoms at Day 18, while symptoms persisted in some patients of the Control Group of patients who were served the same meals without VCO until Day 23, DOST Secretary Fortunato T. dela Peña further stated in the presser.
However, more studies are needed to determine the effectiveness of VCO as adjunct therapy for COVID-19 patients with other co-morbidities, Secretary dela Peña clarified.
In a follow-up interview, Dr. Imelda Angeles-Agdeppa, VCO study leader, Scientist II and Chief Science Research Specialist of DOST-FNRI, said that the study involved 57 suspect or probable COVID-19 cases randomly assigned to the Intervention or VCO Group and the Control Group at the Santa Rosa Community Hospital and Santa Rosa Community Isolation Units in Laguna.
Dr. Agdeppa added that aside from monitoring the signs and symptoms of COVID-19 among the study volunteers, the research team also noted that the mean C-Reactive Protein of CRP levels in the VCO Group normalized to 5 milligrams per liter or less as early as Day 14.
The C-Reactive Protein or CRP is a quantitative marker used to monitor inflammation or infection, and that a CRP equal or less than 5 milligrams per liter signifies recovery from inflammation or infection, Dr. Agdeppa explained.
Dr. Agdeppa further stated that while reduction to normal CRP levels in the Control Group was also evident from Day 1 to 14, it remained at the borderline of 5 milligrams per liter from Day 14 until end of intervention.
The VCO used in the study were strictly analyzed by the Laboratory Services Division of the Philippine Coconut Authority (PCA) to ensure product quality and compliance to Philippine National Standard (PNS).
The PCA requests VCO producers to have their VCO samples analyzed by PCA prior to promotion and marketing, PCA Administrator Benjamin R. Madrigal, Jr. said in the presser.
Funding and monitoring of the VCO study was provided by the DOST-Philippine Council for Health Research and Development (or PCHRD), through the overall supervision and motoring of the DOST.
The Ateneo de Manila University Faculty of Chemistry, through Dr. Fabian M. Dayrit, provided research inputs and protocols based on previous VCO studies among HIV patients, like the correct VCO dosages to be given and the analysis to be used.
Dr. Dayrit, also an Academician of the DOST-National Academy of Science and Technology and President of the Integrated Chemists of the Philippines, supported the results of the DOST-FNRI VCO study, saying that several studies have proven the promising anti-viral properties of VCO and more studies are warranted to explore its full potential.
The public is hereby advised to carefully read the label of VCO products to check for PCA or FDA approval and make sure that ingredients, nutrient analysis, manufacturing and expiration dates are clearly declared.
Some media partners attending the presser commented that this development on VCO as promising dietary supplement may cause the skyrocketing of the price of VCO products.
The study team agrees with this inevitable consequence, but stated that the health benefits backed by scientific proof far outweigh the impending price increase, adding that DTI will monitor this.
This VCO study does not only have promising contribution to the prevention and management of symptoms among COVID-19 suspect and probable cases, but could also provide a boost to the coconut industry and the millions of coconut farmers who depend on the “tree of life” to uplift their quality of life.
For more information on the VCO study and other food and nutrition concerns, contact: Dr. Milflor S. Gonzales, Officer-in-Charge, Office of the Director, Department of Science and Technology – Food and Nutrition Research Institute, General Santos Avenue, Bicutan, Taguig City; Telephone/Fax Nos: 8-837-2934 or 8-837-3164; Direct Line: 8-839-1839; DOST Trunk Line: 837-2071 local 2296 or 2284; e-mail: email@example.com; DOST-FNRI website: http://www.fnri.dost.gov.ph. Like our Facebook Page at facebook.com/DOST.FNRI or follow our Twitter account at twitter.com/DOST_FNRI.
For more COVID treatments:
To read about the numerous deaths/adverse reactions due to this COVID injection, which isn’t a vaccine and doesn’t prevent infection: (list is being updated daily): https://madisonarealymesupportgroup.com/2020/12/21/warning-3150-injuries-in-1st-week-of-covid-vaccines-among-american-healthcare-workers-pregnant-women-included/
The COVID-19 pandemic has been raging through the world for more than a year. More than 455,000 people have died in the US, but the vast majority of people who become infected survive. Unfortunately, for a significant proportion, symptoms associated with COVID-19 may last for weeks or months. Physicians have dubbed this post-COVID syndrome, or PCS. Patients are more likely to call it Long COVID and refer to themselves as Long Haulers.
Long COVID may affect people of any age, not just older individuals. One study found that half of the college students in the sample who had had COVID-19 were still struggling with symptoms like fatigue and trouble exercising, shortness of breath, chest pain, reduced sense of smell, runny nose and loss of appetite more than a month later (MedRxiv, Nov. 29, 2020). Although health care providers have learned a great deal about caring for people with the acute disease, they still don’t have established protocols to help those with long-lasting problems.
For several decades, before the pandemic began, doctors debated how to help patients with lasting symptoms from infections such as Lyme disease. At first, many experts denied that patients’ problems were due to the infection. Instead, they insisted that chronic Lyme didn’t exist.
However, people experiencing those symptoms themselves sought ways to manage them holistically. Some of the approaches they have used may be helpful for individuals who are now suffering with post-COVID syndrome.
Our guest, Dr. Bill Rawls, was frustrated that mainstream medicine had so little to offer him while he fought chronic Lyme disease. He went to the medical literature and devised treatments based on scientific studies of herbal medicines. These helped him and he has since helped others challenged by chronic immune dysfunction, whether triggered by infection or not. Now he is offering guidance to people with Long COVID.
The herbs Dr. Rawls used for his own treatment included Japanese knotweed, cat’s claw, Chinese skullcap, and Andrographis paniculata, along with mushrooms such as Reishi and Cordyceps. Presumably many of these help regulate the immune system’s response. Some experts suspect that a chronic hyperactivation of the immune system might contribute to the symptoms of Long COVID. Dr. Rawls offers his recommendations for what people may want to do as they recover from COVID-19 to reduce their chances of post-COVID syndrome.
Dr. Bill Rawls is a licensed physician with over 30 years of experience and a leading expert in Lyme disease, holistic health, and herbal medicine. In the middle of his successful medical career, Dr. Rawls’ life was interrupted by Lyme disease. In his journey to overcome it, he explored nearly every treatment possible – from conventional medicine to a range of alternative therapies. In the more than 10 years since his recovery, Dr. Rawls has helped thousands of patients to recover from chronic illness and maintain wellness.
He is the author of the best-selling book Unlocking Lyme. He is the Medical Director of RawlsMD.com and Vital Plan, an online holistic health company and Certified B Corporation® that he co-founded with his daughter Braden.
The podcast of this program will be available Monday, February 8, 2021, after broadcast on February 6. The show can be streamed online from this site and podcasts can be downloaded for free. CDs may be purchased at any time after broadcast for $9.99.
I have the same skepticism of “post COVID syndrome” as I do “post Lyme disease syndrome.” Too often our public ‘authorities’ cause the very problems they then attempt to cover-up, by doing a bait and switch and giving it a jazzy name so we forget their role. Disease is often complicated and tying a pretty bow on it by giving it a cool sounding label doesn’t make it any simpler.
The PTLDS moniker continues to hurt patients by keeping them from life-saving antimicrobials. The studies done and used to “prove” chronic infection doesn’t exist all have design flaws. We know for a fact that treatment failures are seen in nearly every single antibiotic study ever done.
There are potentially many reasons for “post COVID syndrome” and other adverse reactions/deaths, including vaccination. Please see: https://madisonarealymesupportgroup.com/2020/08/17/correlation-coefficient-covid-deaths-qivc-flu-shots/
More is coming out about “pathogenic priming,” antibody-dependent enhancement (ADE), vaccine hypersensitivity (VAH), and multi-inflammatory syndrome (MIS) in the many adverse reactions and deaths occurring after the COVID shot. Many are also becoming infected after the shot but we are continually told it can’t be due to the injection. Back in October it was stated these injections could increase HIV risk: https://nypost.com/2020/10/20/some-covid-19-vaccines-could-increase-hiv-risk-researchers/
Please watch Dr. Weiler explain the history of coronavirus vaccines that made animals sicker and killed many, as well as the unsafe epitopes: https://madisonarealymesupportgroup.com/2020/12/04/medical-freedom-press-conference-must-see-video/
The following quote is quite telling:
Is it possible that some instances of ‘long COVID’ could be a form of ADE? This is a possibility we have been considering. Typically people who get long COVID don’t test as positive from nasopharyngeal swab tests. But in deep seated systemic infections the mucosa may not show evidence of viral multiplication, whereas the infection may become systemic in certain tissues and be enhanced. This possibility cannot easily be dismissed.
Could the problem increase with new variants of SARS-CoV-2? Yes, as explained above. Rob Verkerk Ph.D.
The case, involving a 19-year-old Hispanic man, was published in the Italian Journal of Pediatrics.1
Ten weeks after travelling to New York, the patient was diagnosed with the tick-borne illness Babesia. Initially, he presented with a 4-day history of fever, generalized weakness, and flu-like symptoms.
His fever was 104.8 F. His hemoglobin dropped from 9.3g/dL to 6.7g/dL within 5 hours. He was diagnosed with hemolysis and transfused with 2 units of packed red blood cells. A peripheral blood smear revealed a Maltese cross typically seen in Babesia.
Babesia is more likely to be symptomatic in individuals with a history of a splenectomy. This young man had a history of a splenectomy for hereditary spherocytosis when he was 3 years old.
Early in the disease, Babesia is more likely to be diagnosed with a thick blood smear under the microscope. But later in the course of the disease, a polymerase chain reaction (PCR) or antibody test can confirm the infection.
Babesia is more likely to be contracted in the Northeastern region of the United States. This young man had returned from a trip to New York. The disease is less likely to be contracted in Florida where the young man presented to an emergency room.
The patient was prescribed Quinine, but it was stopped due to headache, tinnitus, and blurred vision. Instead, he was successfully treated with Atovaquone, clindamycin, and azithromycin.
Two newborns with delayed onset Babesia
During their third trimester, two mothers were treated for Lyme disease with amoxicillin. Both babies were born and discharged home. But several weeks later, the babies became ill with Babesia.²
The following questions are addressed in this Inside Lyme Podcast.
Editor’s note: Delayed onset Babesia in two newborns is discussed in another Inside Lyme podcast.
Please remember that the advice given is general and not intended as specific advice as to any particular patient. If you require specific advice, then please seek that advice from an experienced professional.
This Inside Lyme case series will be discussed on my Facebook and made available on podcast and YouTube. As always, it is your likes, comments, and shares that help spread the word about this series and our work. If you can, please leave a review on iTunes or wherever else you get your podcasts.